BofA Maintains Underperform Rating on GoodRx (GDRX) While Trimming PT to $2.60

GoodRx Holdings Inc. (NASDAQ:GDRX) is one of the oversold stocks to buy now. On January 5, Bank of America analyst Allen Lutz lowered the firm’s price target on GoodRx to $2.60 from $3 and kept an Underperform rating on the shares. For the broader drug distributor sector, however, the firm remained positive heading into 2026 and adjusted its price targets to align with recent changes in valuation multiples across the peer group.

Additionally, Morgan Stanley reduced its price target for GoodRx from $5 to $4 while maintaining an Equal Weight rating on December 18. In a 2026 outlook for the Healthcare Services sector, the firm noted that while healthcare tech and providers offer an attractive backdrop for alpha-generation, the managed care segment continues to struggle.

BofA Maintains Underperform Rating on GoodRx (GDRX) While Trimming PT to $2.60

On December 8, Barclays initiated coverage of GoodRx with an Underweight rating and a $3 price target. While the firm established a Neutral outlook on the broader US healthcare tech and distribution industry, it expressed the most optimism toward drug distributors. In contrast, Barclays maintained a more cautious and mixed perspective on the dental and healthcare IT sub-sectors.

GoodRx Holdings Inc. (NASDAQ:GDRX), together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the US.

While we acknowledge the potential of GDRX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GDRX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.